Skip to main content
NCBI home page
Gut logoLink to Gut
. 1999 Sep;45(Suppl 2):II69–II77. doi: 10.1136/gut.45.2008.ii69

Design of treatment trials for functional gastrointestinal disorders

S J O V van Zanten, N Talley, P Bytzer, K Klein, P Whorwell, A Zinsmeister
PMCID: PMC1766689  PMID: 10457048

Abstract

Until recently many clinical trials of functional gastrointestinal disorders (FGIDs) suffered from important weaknesses in trial design, study execution, and data analysis. This makes it difficult to determine whether truly efficacious therapies exist for these disorders. One of the important methodologic problems is the absence of validated outcome measures and lack of consensus among stakeholders on how to measure outcome. Currently much of the effort is being put into the development of validated outcome measures for several of the FGIDs. The randomized, controlled trial with parallel groups is the design of choice. In this report, guidelines are given for the basic architecture of intervention studies of FGIDs. Further studies on design issues are required to ensure the recommendations will become evidence based in the future.


Keywords: clinical trial; random allocation; functional gastrointestinal disorder(s); dyspepsia; functional dyspepsia; irritable bowel syndrome; evidence based medicine; study design; outcome measures; Rome II

Full Text

The Full Text of this article is available as a PDF (103.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G. Randomisation. BMJ. 1991 Jun 22;302(6791):1481–1482. doi: 10.1136/bmj.302.6791.1481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K. F., Simel D. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996 Aug 28;276(8):637–639. doi: 10.1001/jama.276.8.637. [DOI] [PubMed] [Google Scholar]
  3. Bero L., Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995 Dec 27;274(24):1935–1938. doi: 10.1001/jama.274.24.1935. [DOI] [PubMed] [Google Scholar]
  4. Dimenäs E., Glise H., Hallerbäck B., Hernqvist H., Svedlund J., Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995 Nov;30(11):1046–1052. doi: 10.3109/00365529509101605. [DOI] [PubMed] [Google Scholar]
  5. Freiman J. A., Chalmers T. C., Smith H., Jr, Kuebler R. R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med. 1978 Sep 28;299(13):690–694. doi: 10.1056/NEJM197809282991304. [DOI] [PubMed] [Google Scholar]
  6. Guyatt G. H., Feeny D. H., Patrick D. L. Measuring health-related quality of life. Ann Intern Med. 1993 Apr 15;118(8):622–629. doi: 10.7326/0003-4819-118-8-199304150-00009. [DOI] [PubMed] [Google Scholar]
  7. Guyatt G. H., Veldhuyzen Van Zanten S. J., Feeny D. H., Patrick D. L. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ. 1989 Jun 15;140(12):1441–1448. [PMC free article] [PubMed] [Google Scholar]
  8. Hahn B. A., Kirchdoerfer L. J., Fullerton S., Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther. 1997 Jun;11(3):547–552. doi: 10.1046/j.1365-2036.1997.00168.x. [DOI] [PubMed] [Google Scholar]
  9. Hawthorne A. B., Logan R. F., Hawkey C. J., Foster P. N., Axon A. T., Swarbrick E. T., Scott B. B., Lennard-Jones J. E. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992 Jul 4;305(6844):20–22. doi: 10.1136/bmj.305.6844.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Houghton L. A., Heyman D. J., Whorwell P. J. Symptomatology, quality of life and economic features of irritable bowel syndrome--the effect of hypnotherapy. Aliment Pharmacol Ther. 1996 Feb;10(1):91–95. doi: 10.1111/j.1365-2036.1996.tb00181.x. [DOI] [PubMed] [Google Scholar]
  11. Jaeschke R., Singer J., Guyatt G. H. A comparison of seven-point and visual analogue scales. Data from a randomized trial. Control Clin Trials. 1990 Feb;11(1):43–51. doi: 10.1016/0197-2456(90)90031-v. [DOI] [PubMed] [Google Scholar]
  12. Jaeschke R., Singer J., Guyatt G. H. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989 Dec;10(4):407–415. doi: 10.1016/0197-2456(89)90005-6. [DOI] [PubMed] [Google Scholar]
  13. Klauser A. G., Voderholzer W. A., Knesewitsch P. A., Schindlbeck N. E., Müller-Lissner S. A. What is behind dyspepsia? Dig Dis Sci. 1993 Jan;38(1):147–154. doi: 10.1007/BF01296788. [DOI] [PubMed] [Google Scholar]
  14. Klein K. B. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology. 1988 Jul;95(1):232–241. doi: 10.1016/0016-5085(88)90319-8. [DOI] [PubMed] [Google Scholar]
  15. Lavori P. W., Louis T. A., Bailar J. C., 3rd, Polansky M. Designs for experiments--parallel comparisons of treatment. N Engl J Med. 1983 Nov 24;309(21):1291–1299. doi: 10.1056/NEJM198311243092105. [DOI] [PubMed] [Google Scholar]
  16. MacKenzie C. R., Charlson M. E. Standards for the use of ordinal scales in clinical trials. Br Med J (Clin Res Ed) 1986 Jan 4;292(6512):40–43. doi: 10.1136/bmj.292.6512.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975 Sep;1(3):277–299. doi: 10.1016/0304-3959(75)90044-5. [DOI] [PubMed] [Google Scholar]
  18. O'Donoghue D. P., Dawson A. M., Powell-Tuck J., Bown R. L., Lennard-Jones J. E. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978 Nov 4;2(8097):955–957. doi: 10.1016/s0140-6736(78)92524-2. [DOI] [PubMed] [Google Scholar]
  19. Oxman A. D., Guyatt G. H. A consumer's guide to subgroup analyses. Ann Intern Med. 1992 Jan 1;116(1):78–84. doi: 10.7326/0003-4819-116-1-78. [DOI] [PubMed] [Google Scholar]
  20. Patrick D. L., Drossman D. A., Frederick I. O., DiCesare J., Puder K. L. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998 Feb;43(2):400–411. doi: 10.1023/a:1018831127942. [DOI] [PubMed] [Google Scholar]
  21. Perneger T. V. What's wrong with Bonferroni adjustments. BMJ. 1998 Apr 18;316(7139):1236–1238. doi: 10.1136/bmj.316.7139.1236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rösch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol. 1987 Mar;22(2):161–164. doi: 10.3109/00365528708991874. [DOI] [PubMed] [Google Scholar]
  23. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986 Sep;105(3):429–435. doi: 10.7326/0003-4819-105-3-429. [DOI] [PubMed] [Google Scholar]
  24. Smith D. G., Clemens J., Crede W., Harvey M., Gracely E. J. Impact of multiple comparisons in randomized clinical trials. Am J Med. 1987 Sep;83(3):545–550. doi: 10.1016/0002-9343(87)90768-6. [DOI] [PubMed] [Google Scholar]
  25. Talley N. J., Silverstein M. D., Agréus L., Nyrén O., Sonnenberg A., Holtmann G. AGA technical review: evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology. 1998 Mar;114(3):582–595. doi: 10.1016/s0016-5085(98)70542-6. [DOI] [PubMed] [Google Scholar]
  26. Talley N. J., Weaver A. L., Tesmer D. L., Zinsmeister A. R. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology. 1993 Nov;105(5):1378–1386. doi: 10.1016/0016-5085(93)90142-y. [DOI] [PubMed] [Google Scholar]
  27. Veldhuyzen van Zanten S. J., Cleary C., Talley N. J., Peterson T. C., Nyrén O., Bradley L. A., Verlinden M., Tytgat G. N. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol. 1996 Apr;91(4):660–673. [PubMed] [Google Scholar]
  28. Veldhuyzen van Zanten S. J., Tytgat K. M., Pollak P. T., Goldie J., Goodacre R. L., Riddell R. H., Hunt R. H. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol. 1993 Mar;46(3):273–279. doi: 10.1016/0895-4356(93)90075-c. [DOI] [PubMed] [Google Scholar]
  29. Woods J. R., Williams J. G., Tavel M. The two-period crossover design in medical research. Ann Intern Med. 1989 Apr 1;110(7):560–566. doi: 10.7326/0003-4819-110-7-560. [DOI] [PubMed] [Google Scholar]
  30. el-Omar E. M., Banerjee S., Wirz A., McColl K. E. The Glasgow Dyspepsia Severity Score--a tool for the global measurement of dyspepsia. Eur J Gastroenterol Hepatol. 1996 Oct;8(10):967–971. doi: 10.1097/00042737-199610000-00006. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES